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shows linear pricing is the most frequent approach for MABs in Italy. Financial MEAs 
and appropriateness-registries are widely applied, with several cases of multiple 
measures in place for the same MAB. Time to approval is still quite substantial, 1.2 
years on average over the last 5 years.
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Objectives: Interest in Real World Evidence (RWE), data not collected via tradi-
tional randomised controlled trials (RCT) used in different contexts, is increas-
ing for market-access and reimbursement decision-makers. A global survey was 
undertaken to understand the use of RWE in these contexts. MethOds: The survey 
tool, 35 qualitative and quantitative open- and closed-ended questions, was devel-
oped iteratively with stakeholders (academia, health services, government bodies, 
patient organisations). The tool, available in English via Qualtrics from March 2017, 
included questions on the use of RWE for licensing and coverage recommendations, 
RWE ownership and the future of RWE. The survey was distributed to a selection of 
global contacts (n= 260). Results: We analysed preliminary results for 46 returned 
surveys. Respondents were from 20 countries and a variety of roles (academia, HTA 
bodes, clinicians and patient organisations). Over two-thirds (69%, n= 24) thought it 
unlikely RWE would support licensing and market authorisation-related decision-
making, 91% (32) thought it more likely that RWE would have a role in national-level 
HTA periodic re-assessment. Less than 40% thought that RWE would ever play a 
similar role to RCT in drug evaluations, although 14 countries reported accept-
ing lower levels of evidence for decision-making. Respondents from Spain, Russia, 
Cyprus, Bulgaria, Romania, France and the UK saw potential in the use of RWE in 
regulatory, reimbursement, and clinical based decision-making, economic evalu-
ations and reassessment-re-review in the next 3-5 years. Those from Bosnia and 
Herzegovina, Belgium, Austria, Italy and Germany saw less potential. Barriers to 
RWE use included issues around lack of randomisation, lack of data availability and 
data quality. cOnclusiOns: Whilst there are some differing opinions around the 
use of RWE for regulatory purposes, most respondents see it as a complement to 
RCT, rather than a replacement. The general opinion is that RWE will become more 
valuable over time if data quality and availability can be improved.
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Objectives: The 2006 FDA-UDI was implemented to identify and remove unsafe/ 
ineffective drugs from the market. Manufacturers of such drugs could conduct 
studies to prove safety and/or efficacy and file a New Drug Application, for which 
approval provided limited market exclusivity. To date, there has been very little 
research on the potential consequences of this policy on post-approval prices and 
quantities sold for these drugs. This objective of this study was to assess the impact 
on prices and quantities sold for drugs that have been approved within the FDA-
UDI in the US. MethOds: The DESI-II list prepared by the FDA Prescription Drug 
Wrap-Up program of 1984 was systematically searched to identify unapproved 
marketed drugs that were single-entity prescription drugs. For the drugs which 
obtained voluntary FDA approval within the FDA-UDI between 2006-2015, a retro-
spective longitudinal analysis was conducted based on the IMS Health National 
Sales Perspective database to analyze trends in total expenditures, units sold, and 
price/unit where all prices were adjusted to 2016 dollars. Results: Eighteen previ-
ously-marketed unapproved drug products were identified and 17 were included in 
the analysis (Neostigmine was excluded due to a shortage unrelated to the policy). 
Compared to the baseline price measured at two years pre-approval, 11 showed 
increases in the price/unit two years post-approval ranging from 27% to 8820%, while 
a decline in price was observed for the remaining six drugs. In addition, 12 showed 
a decline in quantity two years post-approval (range 2%-93%) while increases were 
observed for remaining five drugs. Substantial variance was also seen in the changes 
in expenditures, and in the implied price elasticities. cOnclusiOns: A marked 
increase was seen in post-approval prices along with decreases in quantities sold 
for most of the drugs approved in the FDA-UDI. However, the impact associated with 
the policy varied substantially across different drug products.
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Objectives: Japan has the following pricing guidance: a premium is possible to be 
applied for an Orphan Designated drug if the premium has not been applied to its 
comparator. The objective of this study is to compare National Healthcare Insurance 
(NHI) prices of Orphan Designated drugs with Reference Countries’ prices (listed 
in US: Red Book; UK: MIMS; Germany: Rote Liste; France: Vidal) at the time of NHI 
price listing. MethOds: NHI price information was obtained from official websites 
pre-reform period. In all, the pharmaceutical reform as a whole failed to meet its 
goal of combating sharp growth of drug and total health expenditure.
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Objectives: Despite the wide use of Health Technology Assessment (HTA) in some 
countries, common understanding of value definition and attributes that contribute 
to value in healthcare is lacking. In response to the debate on access to expen-
sive drugs, various drug value frameworks (VFs) have emerged in recent years. 
This research aims at comprehensive identification of existing “non-HTA” VFs in 
the context of this current debate. MethOds: Comprehensive literature review 
of Medline and Japanese ICHUSHI database, websites of ESMO, EU Cancer Patient 
Coalition, OECD, ASCO, NCCN, and other scientific/governmental organisations was 
conducted with no time restrictions up to April, 2017 year to identify VFs others 
than used by HTA agencies. A descriptive analysis was performed to characterise 
VFs and trends in their development. Results: 54 non-HTA VFs were identified. 
From 2011, a dynamic increase in new VFs was observed at 42% average annual rate 
with the highest nominal growth in 2015-2016 (24 new VFs). Most VFs originate from 
the United States (US) and Europe (70%) and are targeted at global (N= 25), European 
(N= 14), US (N= 13) or other country’s stakeholders (N= 2). VFs are to determine value 
of therapies in all indications (N= 27) or in oncology only (N= 16). VFs aimed at fund-
ing/clinical decision-making prevail (57%) followed by those informing R&D (19%). 
90% of new VFs targeted at funding/clinical decision-making in 2015 were dedicated 
to oncology area. ESMO’s Magnitude of Clinical Benefit Scale, ASCO’s Conceptual 
Framework, DrugAbacus tool, NCCN Evidence Blocks and ICER value assessment 
Framework are amidst key recent VFs. cOnclusiOns: VFs others than those used 
by HTA agencies are gaining importance but their current impact on decision-mak-
ing is minor. More practicability and validity are expected to enhance their wider 
adoption. HTA agencies in Europe are showing increased interest in such VFs, which 
may end up more influential in Europe than in the US.
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Objectives: Manufacturers are committed to submit a dossier to the G-BA for an 
early benefit assessment of new drugs in Germany. The G-BA evaluates the dossier 
and decides about the added benefit of the drug versus the appropriate comparator. 
The decision on added benefit can be time restricted and reassessed after the dead-
line. The aim of this study is to give an overview of all time restricted and reassessed 
processes, to extract the reasons for a time restriction and to compare the decisions 
on added benefit of the initial assessment and the reassessment. MethOds: The 
G-BA decisions on added benefit and the rationale for all processes were retrieved up 
to March 15th, 2017 from the G-BA homepage. Extraction included active substance, 
indication, therapeutic area, G-BA decisions and rationales. Results: 37 of all 238 
decisions were time restricted. Of these, 15 had already been reassessed. Orphan 
drugs, oncology drugs and drugs with conditional approval were especially prone 
to receive a time restriction. Common reasons for time restriction were missing 
data which needed to be generated for EMA or incomplete data on patient-relevant 
endpoints. The most common restriction period was 2.5 years. The added benefit 
in reassessments improved in 4 of 15 processes and deteriorated in another 4 of 
15 processes. In 7 of 15 processes the added benefit did not change. A common 
reason for improvement was new data available, while for deterioration missing 
new data or new evident data which refuted the first decision was most com-
mon. cOnclusiOns: A time restricted decision by G-BA frequently affects drugs 
with unsatisfactory data. Reassessment can improve added benefit if convincing 
new evidence is available.
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Objectives: Monoclonal antibodies (MABs) have been on the Italian market for 
nearly 20 years. We explored the different aspects of Market Access (MA) for MABs 
by disease area (DA) (autoimmune, oncology, rare, asthma, diagnostics, dyslipidemia, 
other), in order to highlight possible trends. MethOds: Information was retrieved 
from EMA and AIFA websites. Analysis was focused on type of pricing, average 
time to approval (TTA), presence of monitoring registries (MR) and managed entry 
agreements (MEA) for all MABs approved in Italy (1998 to April 2017). For pricing, 
we considered drugs with multiple formulations and defined three classes: lin-
ear (proportional price-dosage); semi-linear (non-proportional price-dosage); flat 
(equal price, regardless of dosage). Average TTA was analyzed by year, calculated as 
the difference between AIFA and EMA approval dates, divided by number of MABs 
approved in the year over the whole 20 years, last 10 and last 5 years. Presence/type 
of MR and MEAs were recorded and analyzed. Results: 43 MABs were included, 
showing clear trend for linear pricing particularly in oncology (90%) and autoim-
mune diseases (60%). Average TTA was 409 days (1998-2017); 439 days (2008-2017) 
and 441 days (2013-2017), with wide variations: diagnostics 570, dyslipidemia 542, 
rare diseases 516, oncology 421 days. 21 (49%) of all MABs (75% in oncology) are cur-
rently subject to a total of 33 MR: 81%(17/21) for appropriateness of use, 55%(12/21) 
outcome-based, 21%(5/21) financial-based, as most MABs have > 1 registry in place 
(eg. for different indications). Intersection of MR with MEAs yields a total of 47 agree-
ments for 25 MABs, at increasing trend over years. cOnclusiOns: Our analysis 
